Press release
Neurofibromatosis Type 2 Treatment Market Size in the 7MM was approximately USD 60 million in 2023, estimated DelveInsight
DelveInsight's "Neurofibromatosis Type 2 Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Neurofibromatosis Type 2, historical and forecasted epidemiology as well as the Neurofibromatosis Type 2 market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Neurofibromatosis Type 2 Market by downloading the comprehensive report from DelveInsight @ Neurofibromatosis Type 2 Treatment Market Size [https://www.delveinsight.com/sample-request/neurofibromatosis-2-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Neurofibromatosis Type 2 Market Report
* In September 2024:- AstraZeneca- A Phase III, Multicentre, International Study With a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET). A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.
* In the 7MM, the total diagnosed prevalent cases of Neurofibromatosis type 2 (NF2) in 2023 were approximately 16,976. As per the estimates by DelveInsight, these cases are expected to increase at a substantial CAGR for the study period of 2020-2034.
* Assessments as per DelveInsight's analysts showed that in 2023 there were nearly 1,695 diagnosed prevalent cases of NF2 in children and adolescents and 8,897 cases in adults in the US. The overall cases are subjected to increase rapidly in the forecast period (2023-2034).
* The leading Neurofibromatosis Type 2 Companies such as Recursion Pharmaceuticals Inc., Betta Pharmaceuticals Co., Ltd., Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd, Novartis Pharmaceuticals, Genentech Inc., GlaxoSmithKline, AstraZeneca, and others.
* Promising Neurofibromatosis Type 2 Therapies such as REC-2282, HLX-1502, Vismodegib, Capivasertib, Brigatinib, Neratinib, and others
Gain a competitive edge in the Neurofibromatosis Type 2 Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Neurofibromatosis Type 2 Treatment Drugs [https://www.delveinsight.com/sample-request/neurofibromatosis-2-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Neurofibromatosis Type 2 Epidemiology Segmentation in the 7MM
* Neurofibromatosis Type 2 Age-specific Diagnosed Prevalent Cases
* Total Neurofibromatosis Type 2 Diagnosed Prevalent Cases
* Neurofibromatosis Type 2 Tumor-specific Diagnosed Prevalent Cases
Neurofibromatosis Type 2 Market Insights
Neurofibromatosis Type 2 (NF2) presents with management dilemmas, as the current treatment options for NF2-related tumors provide only temporary benefits, and there are no FDA-approved pharmacologic therapies. The mainstay of management of NF2 is the surgical removal of symptomatic cranial and spinal tumors with regular monitoring. Tumors developing inside the brain and spinal cord can place a strain on the body and shorten life expectancy.
Discover key developments and opportunities in the Neurofibromatosis Type 2 Market. Click here to learn more from DelveInsight's latest report @ Neurofibromatosis Type 2 Market Size [https://www.delveinsight.com/sample-request/neurofibromatosis-2-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Neurofibromatosis Type 2 Emerging Drugs Profile
* REC-2282: Recursion Pharmaceuticals Inc.
* VT3989: Vivace Therapeutics, Inc.
Neurofibromatosis Type 2 Therapeutics Market Landscape
The current market of NF2 is more or less dependent on supportive care such as Chemotherapy, corticosteroids, dexamethasone, others. At present, international studies have found that some drugs can effectively control or even reduce the size of tumors. Currently the use of drugs to treat NF2 has also gathered huge audience and active participation. Reduce tumor volume and control tumor growth through oral or intravenous injection of drugs has been observed with the use of Bevacizumab. Currently the Neurofibromatosis Type 2 therapeutics market has several key players involved in developing therapies. The emerging therapies are expected to create a significant positive shift in NF2 market size.
Download DelveInsight's Neurofibromatosis Type 2 Market report today and stay ahead in this rapidly evolving field. @ Neurofibromatosis Type 2 Clinical Trials [https://www.delveinsight.com/sample-request/neurofibromatosis-2-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Neurofibromatosis Type 2 Market Report
* Coverage- 7MM
* Neurofibromatosis Type 2 Companies- Recursion Pharmaceuticals Inc., Betta Pharmaceuticals Co., Ltd., Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd, Novartis Pharmaceuticals, Genentech Inc., GlaxoSmithKline, AstraZeneca, and others.
* Neurofibromatosis Type 2 Therapies- REC-2282, HLX-1502, Vismodegib, Capivasertib, Brigatinib, Neratinib, and others
* Neurofibromatosis Type 2 Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Neurofibromatosis Type 2 Unmet Needs, KOL's views, Analyst's views, Neurofibromatosis Type 2 Market Access and Reimbursement
Download the report to understand which factors are driving Neurofibromatosis Type 2 Market Trends @ Neurofibromatosis Type 2 Market Trends [https://www.delveinsight.com/sample-request/neurofibromatosis-2-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Key Insights
2. Executive Summary of Neurofibromatosis Type 2
3. Competitive Intelligence Analysis for Neurofibromatosis Type 2
4. Neurofibromatosis Type 2: Market Overview at a Glance
5. Neurofibromatosis Type 2: Disease Background and Overview
6. Patient Journey
7. Neurofibromatosis Type 2 Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Neurofibromatosis Type 2 Unmet Needs
10. Key Endpoints of Neurofibromatosis Type 2 Treatment
11. Neurofibromatosis Type 2 Marketed Products
12. Neurofibromatosis Type 2 Emerging Therapies
13. Neurofibromatosis Type 2: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Neurofibromatosis Type 2
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neurofibromatosis-type-2-treatment-market-size-in-the-7mm-was-approximately-usd-60-million-in-2023-estimated-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurofibromatosis Type 2 Treatment Market Size in the 7MM was approximately USD 60 million in 2023, estimated DelveInsight here
News-ID: 3668107 • Views: …
More Releases from ABNewswire
Understanding CBT Therapy: What a CBT Therapist Does and How It Helps
CBT therapy helps people change unhelpful thoughts and behaviours through practical techniques. A CBT therapist guides you to manage issues like anxiety, depression, or stress, whether face-to-face or with a CBT therapist online. If you're searching "CBT therapist near me" or wondering "what is a CBT therapy?", CBT can provide effective, lasting support.
In today's world, many people are turning to therapy to better understand their thoughts, feelings, and behaviours. Among…
Don't Miss Out: Discounted 2025 Georgia Bulldogs Football Tickets with Promo Cod …
CapitalCityTickets.com offers discounted 2025 Georgia Bulldogs football tickets, including games at Mercedes-Benz Stadium. Fans can use promo code CITY5 to receive additional savings on any order. The platform provides a 100% guarantee on all tickets, ensuring secure transactions and timely delivery. With a user-friendly interface, fans can easily browse and select their preferred seats for upcoming games.
Get ready to cheer "Go Dawgs!" in the 2025 college football season! The Georgia…
Best Deals on 2025 Bryan Adams Tickets - Use Promo Code CITY10 at CapitalCityTic …
Score the best deals on 2025 Bryan Adams tickets at CapitalCityTickets.com! All seating levels are on sale, making it easy to find the perfect spot for his legendary live shows. Use promo code CITY10 to unlock extra savings and enjoy an unforgettable concert experience. Don't miss your chance to hear Bryan Adams perform his greatest hits live-shop today and secure affordable tickets for a night of timeless music and energy!
Rock…
Pie Recognised as a Leading Tax Software in the UK
Pie Money Limited has been recognised as one of the top tax software in the UK. With real-time tax calculations, HMRC submissions, and smart bookkeeping tools, Pie is helping freelancers, contractors, and small businesses file taxes quickly and with confidence. Founder Tommy Mcnally says: "It's your money. Claim it." Trusted by thousands, Pie is redefining the way UK taxpayers approach Self Assessment and online tax filing.
LONDON, United Kingdom - 9…
More Releases for Neurofibromatosis
Neurofibromatosis Type 2 (NF2) Market Massive Growth opportunity Ahead
Introduction
Neurofibromatosis Type 2 (NF2) is a rare genetic disorder caused by mutations in the NF2 gene, leading to the development of benign tumours on the brain, spinal cord, and peripheral nerves. The hallmark of NF2 is bilateral vestibular schwannomas, which can cause hearing loss, balance issues, and neurological complications. While the condition is non-malignant, its progressive nature and impact on quality of life make it a serious healthcare challenge.
Currently, there…
Neurofibromatosis Market Dynamics Indicate Upward Trajectory Through 2032, Repor …
DelveInsight's "Neurofibromatosis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Neurofibromatosis, historical and forecasted epidemiology as well as the Neurofibromatosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Neurofibromatosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurofibromatosis Market Forecast
https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Neurofibromatosis…
Neurofibromatosis Type-1 Market Is Booming Worldwide - AstraZeneca, GlaxoSmithKl …
Neurofibromatosis Type-1 Market Insights
The Neurofibromatosis Type-1 Market is projected to reach USD 2.4 billion by 2032, growing at a CAGR of 7.2% during the forecast period (2025-2032).
Coherent Market Insights has published a new comprehensive analysis on the Neurofibromatosis Type-1 Market (2025-2032), focusing on critical transformations in the U.S. healthcare environment. This report highlights essential metrics including market size, revenue forecasts, CAGR, adoption trends, and regulatory drivers. Backed by clinical evidence…
Neurofibromatosis Treatment Market Size, Industry And Forecast To 2033
The new report published by The Business Research Company, titled Neurofibromatosis Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the neurofibromatosis treatment market size has grown rapidly in recent years. It will grow from $11.41 billion in 2023…
Neurofibromatosis Treatment Market Research Analysis, Application And Forecast T …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Neurofibromatosis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $21.58 billion In 2028 At…
Neurofibromatosis Treatment Market to Set Phenomenal Growth by 2023
Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumors may develop anywhere in the nervous system of the victim, which may include the brain, spinal cord and nerves. Neurofibromatosis is usually diagnosed in childhood or early adulthood. The tumors are noncancerous (benign) in most of the cases, but in some cases these tumors become cancerous…
